Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience

被引：10

作者：

Memoli, Mara ^{[1
,2
]}

Paviglianiti, Annalisa ^{[1
]}

Malard, Florent ^{[1
,3
,4
]}

Battipaglia, Giorgia ^{[1
,4
]}

Brissot, Eolia ^{[1
,3
,4
]}

Mediavilla, Clemence ^{[1
,4
]}

Bianchessi, Antonio ^{[1
,5
]}

Banet, Anne ^{[1
]}

Van de Wyngaert, Zoe ^{[1
]}

Ledraa, Tounes ^{[1
]}

Belhocine, Ramdane ^{[1
]}

Sestili, Simona ^{[1
]}

Lapusan, Simona ^{[1
]}

Hirsch, Pierre ^{[3
,4
,6
]}

Favale, Fabrizia ^{[3
,4
,6
]}

Boussaroque, Agathe ^{[3
,4
,6
]}

Bonnin, Agnes ^{[1
]}

Vekhoff, Anne ^{[1
]}

Legrand, Ollivier ^{[1
,3
,4
]}

Mohty, Mohamad ^{[1
,3
,4
]}

Dulery, Remy ^{[1
,3
,4
]}

机构：

[1] St Antoine Hosp, AP HP, Dept Hematol & Cellular Therapy, 184 Rue Faubourg St Antoine, F-75012 Paris, France

[2] Univ Naples Federico II, Hematol & Hematopoiet Stem Cell Transplant Ctr, Dept Med & Surg, Naples, Italy

[3] INSERM, UMRs 938, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP, Paris, France

[5] Univ Pavia, Dept Mol Med, Pavia, Italy

[6] Hop St Antoine, AP HP, Serv Hematol Biol, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 02期

关键词：

Thiotepa; busulfan; fludarabine; HSCT; TBF; myelofibrosis; STEM-CELL TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; LEUKEMIA WORKING PARTY; HAPLOIDENTICAL TRANSPLANTATION; EUROPEAN-SOCIETY; RISK-FACTORS; MARROW; SPLENECTOMY; RUXOLITINIB; MANAGEMENT;

D O I：

10.1080/10428194.2020.1827246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (n = 5), matched unrelated (n = 16), mismatched unrelated (n = 1), and haploidentical (n = 7). All but 2 patients engrafted. The cumulative incidence (CI) of grade II-IV acute graft-versus-host disease (GVHD) was 21% (95% CI, 10-42) at day 100. The CI of chronic GVHD was 39% (95% CI, 23-65) at 3 years. The median follow-up period was 39 (range 14-60) months. Overall survival was 69% (95% CI, 50-83) at 3 years. No relapse was observed. TBF is a valid conditioning strategy in patients with MF.

引用

页码：419 / 427

页数：9

共 50 条

[11] Allogeneic bone marrow transplantation in patients with hematological malignancy using busulfan, thiotepa, fludarabine as conditioning regimen
Raiola, A. M.
Dominietto, A.
Varaldo, R.
Gualandi, F.
Di Grazia, C.
Lamparelli, T.
Bregante, S.
van Lin, M. T.
Galaverna, F.
Ghiso, A.
Marani, C.
Bacigalupo, A.
BONE MARROW TRANSPLANTATION, 2015, 50 : S221 - S221
[12] Safety and Efficacy of Thiotepa Based Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Single Center Experience
Elcheikh, Jean
Massoud, Radwan
Moukalled, Nour
Haffar, Basel
Zaherddine, Ammar
Maya, Charafeddine
Mahfouz, Rami
Bazarbachi, Ali
BLOOD, 2017, 130
[13] Treosulfan and Fludarabine based Conditioning regimen in Pediatric Patients undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A single centre experience
Foell, J.
Buerle, K.
Dannenmaier, A-K.
Jakob, M.
Rebe, K.
Corbacioglu, S.
BONE MARROW TRANSPLANTATION, 2015, 50 : 5591 - 5591
[14] The Efficacy and Safety of Busulfan Dose Intensity with Fludarabine Conditioning Regimen for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. A Single Center Experience
Massoud, Radwan
Heller, Raban
Moukalled, Nour
Matar, Charbel
Haffar, Basel
Bazarbachi, Ali
El-Cheikh, Jean
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S310 - S311
[15] Busulfan and Fludarabine As Conditioning Regimen for Unrelated Allogeneic Stem Cell Transplant: A Single-Center Experience
Sutamtewagul, Grerk
Abbi, Kamal Kant Singh
Farooq, Umar
Mott, Sarah L.
Dozeman, Lindsay
Silverman, Margarida
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S358 - S358
[16] Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience
Schmohl, Joerg U.
Groh, Christiane
Faul, Christoph
Vogel, Wichard
Moehle, Robert
Wirths, Stefan
Schneidawind, Dominik
Kanz, Lothar
Bethge, Wolfgang A.
ANNALS OF HEMATOLOGY, 2016, 95 (06) : 973 - 983
[17] Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience
Joerg U. Schmohl
Christiane Groh
Christoph Faul
Wichard Vogel
Robert Möhle
Stefan Wirths
Dominik Schneidawind
Lothar Kanz
Wolfgang A. Bethge
Annals of Hematology, 2016, 95 : 973 - 983
[18] Thiotepa, busulfan and fludarabine conditioning regimen for adult patients with lymphoid malignancies undergoing allogeneic stem cell transplantation: a study on behalf of GETH-TC
Pena, M.
Martinez, D. F.
Paviglianiti, A.
Balaguer, A.
Sanz, J.
Pascual, M. J.
Herruzo, B.
Solano, C.
Benzaquen, A.
Salas, M. Q.
Rovira, M.
Nieto, A.
Espanol, I.
Huguet, M.
Bento, L.
Saez, A. J.
Mussetti, A.
BONE MARROW TRANSPLANTATION, 2025,
[19] Treosulfan-Thiotepa-Fludarabine-Based Conditioning Regimen for Allogeneic Transplantation in Patients with Thalassemia Major: A Single-Center Experience from North India
Choudhary, Dharma
Sharma, Sanjeev Kumar
Gupta, Nitin
Kharya, Gaurav
Pavecha, Punita
Handoo, Anil
Setia, Rasika
Katewa, Satyendra
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (03) : 492 - 503
[20] Thiotepa, Busulfan and Fludarabine Conditioning Regimen in Adult Patients Undergoing Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. a Study on Behalf of Geth-TC
Pena, Marta
Paviglianiti, Annalisa
Jesus Pascual, Maria
Herruzo, Beatriz
Solano, Carlos
Benzaquen, Ana
Queralt Salas, Maria
Rovira, Montserrat
Agustin Nieto
Espanol, Ignacio
Marin, Adolfo Jesus Saez
Bento De Miguel, Leyre
Sureda Balari, Anna Maria
Mussetti, Alberto
BLOOD, 2023, 142

← 1 2 3 4 5 →